A randomized, double‐blind, placebo‐controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis
Neurogastroenterology & Motility · 2023
DOI: 10.1111/nmo.14523 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neurogastroenterology & Motility, 2023. Verfasst von Thomas L Abell und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of Louisville, Louisville, Kentucky, USA. Hauptthemen laut MEDLINE: Gastroparesis, Diabetes Mellitus. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Background
This study assessed the efficacy and safety of velusetrag—a 5‐HT 4 agonist with pan‐gastrointestinal prokinetic activity—for gastroparesis symptom management and gastric emptying (GE).
Methods
In this multicenter, double‐blind, randomized, placebo‐controlled study, subjects with diabetic or idiopathic gastroparesis received velusetrag 5, 15, or 30 mg or placebo for 12 weeks. The primary efficacy outcome was a 7‐day mean Gastroparesis Cardinal Symptom Index 24‐h composite score (GCSI‐24H) change from baseline at week 4; GE was evaluated using scintigraphy (GES) and breath tests, and safety from adverse events (AEs). Key Results 232 subjects (183 females; 113 idiopathic gastroparesis) received treatment from February 2015 through June 2017. Least‐squares mean improvement from baseline GCSI‐24H (primary endpoint) at week 4 was −1.5 following velusetrag 5 mg vs −1.1 following placebo (treatment difference, −0.4; 95% confidence interval, −0.75 to −0.03; nominal p = 0.0327; Hochberg‐adjusted p = 0.0980 [not significant]). Symptom improvement from baseline was achieved only with velusetrag 5 mg, which resulted in greater improvement from baseline vs placebo in all gastroparesis core symptoms, especially in subjects with idiopathic gastroparesis. Improvement from baseline GE by GES was greater in subjects receiving velusetrag (all doses) vs placebo; >70% of subjects receiving velusetrag 30 mg had GE normalization at 4 h. Treatment‐emergent AEs were generally mild. Conclusions and Inferences Velusetrag treatment was generally well‐tolerated and associated with improved GE vs placebo in subjects with diabetic or idiopathic gastroparesis; however, only the lowest dose, velusetrag 5 mg, was associated with short‐term improvement in gastroparesis symptoms. ClinicalTrials .gov NCT02267525.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Louisville, Louisville, Kentucky, USA.
- Massachusetts General Hospital, Boston, Massachusetts, USA.
- University of Kansas Medical School, Kansas City, Kansas, USA.
- Theravance Biopharma US, Inc., South San Francisco, California, USA.
- Alfasigma S.p.A, Bologna, Italy.
- Stanford University School of Medicine, Stanford, California, USA.
ORCID-Profile: Thomas L Abell, Deanna D Nguyen, Linda Nguyen, Nicholas J Talley, Richard McCallum
Zitieren
APA
Abell, T. L., Kuo, B., Esfandyari, T., Pfeifer, N. D., Grimaldi, M., Renzulli, C., Tacchi, R., Zhou, K., Barnes, C. N., Nguyen, D. D., Nguyen, L., Talley, N. J., & McCallum, R. (2023). A randomized, double‐blind, placebo‐controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis. Neurogastroenterology & Motility. https://doi.org/10.1111/nmo.14523
Vancouver
Abell TL, Kuo B, Esfandyari T, Pfeifer ND, Grimaldi M, Renzulli C, et al. A randomized, double‐blind, placebo‐controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis. Neurogastroenterology & Motility. 2023. doi:10.1111/nmo.14523
BibTeX
@article{Abell2023,
author = {Abell, Thomas L and Kuo, Braden and Esfandyari, Tuba and Pfeifer, Nathan D and Grimaldi, Maria and Renzulli, Cecilia and Tacchi, Raffaella and Zhou, Kefei and Barnes, Chris N and Nguyen, Deanna D and Nguyen, Linda and Talley, Nicholas J and McCallum, Richard},
title = {A randomized, double‐blind, placebo‐controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis},
journal = {Neurogastroenterology & Motility},
year = {2023},
doi = {10.1111/nmo.14523}
}
EUVIMED